Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
Janux Therapeutics’ $296.5 Million Common Stock Offering
Amphenol Corp.’s $2.025 Billion Acquisition of Carlisle Interconnect Technologies
Kirkland & Ellis is advising Carlisle Companies Incorporated on the transaction, and Latham & Walkins is advising Amphenol Corporation. Amphenol Corporation (NYSE: APH), a leading global...
AbbVie’s Acquisition of Cerevel Therapeutics
Kirkland & Ellis advised AbbVie, Latham & Watkins advised Cerevel Therapeutics, Skadden advised Centerview partners LLC, as financial advisor to Cerevel Therapeutics in the transaction. AbbVie...
Alpine Immune Sciences’ $150 Million Common Stock Offering
Wilson Sonsini Goodrich & Rosati advised Alpine Immune Sciences on the offering, and Latham & Watkins advised the underwriters. Alpine Immune Sciences, Inc. (Nasdaq: ALPN) announced the...
Hyland Software’s US$3.4 Billion Unitranche Facility Financing
Latham & Watkins represents Golub Capital on the deal. Golub Capital acted as Administrative Agent, Left Lead Arranger, and Joint Bookrunner on a US$3.4 billion unitranche...
Boston Scientific’s $850 Million Acquisition of Relievant MedSystems
Faegre Drinker advised Boston Scientific, and Latham & Watkins advised Relievant MedSystems on the deal. Boston Scientific Corporation (NYSE: BSX) announced it has entered into a...
Gilead’s $2 Billion Senior Unsecured Notes Offering
Davis Polk advised Gilead, and Latham & Watkins advised the underwriters. Gilead Sciences, Inc. (Nasdaq: GILD) announced the pricing of senior unsecured notes in an aggregate...
Thoma Bravo’s Acquisition of NextGen Healthcare
Latham & Watkins advised NextGen Healthcare, Goodwin Procter advised Thoma Bravo, and Skadden advised Morgan Stanley & Co. LLC as financial advisor to NextGen Healthcare on...
VBA’s US$156 Million Growth Funding From Spectrum Equity
Latham & Watkins advises Spectrum Equity in US$156 million growth funding for VBA. VBA, a leader in cloud-based benefits software for healthcare payers, has announced that...
Ikena Oncology’s Acquisition of Pionyr Immunotherapeutics
Latham & Watkins advised Pionyr on the sale. Ikena Oncology, Inc. (Nasdaq: IKNA, Ikena) and Pionyr Immunotherapeutics, Inc. have announced the closing of Ikena’s acquisition of...
PROCEPT BioRobotics’ $172.5 Million Common Stock Offering
Latham & Watkins advised PROCEPT BioRobotics, and Shearman & Sterling advised the underwriters. PROCEPT BioRobotics Corporation announced a follow-on offering of 5,085,494 shares of common stock at...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...